Ado-trastuzumab emtansine (T-DM1) in patients (pts) with HER2 amplified (amp) tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the National Cancer Institute (NCI) Molecular Analysis for Therapy Choice (MATCH) trial Meeting Abstract
| Authors: | Jhaveri, K. L.; Makker, V.; Wang, X. V.; Chen, A. P.; Flaherty, K.; Conley, B. A.; O'Dwyer, P. J.; Williams, P. M.; Hamilton, S. R.; Harris, L.; McShane, L.; Rubinstein, L.; Gray, R. J.; Li, S. L.; Mitchell, E. P.; Patton, D.; Moscow, J.; Zwiebel, J. A.; Arteaga, C. L.; Luoh, S. W. |
| Abstract Title: | Ado-trastuzumab emtansine (T-DM1) in patients (pts) with HER2 amplified (amp) tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the National Cancer Institute (NCI) Molecular Analysis for Therapy Choice (MATCH) trial |
| Meeting Title: | 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 36 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2018 Jun 1-5 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2018-05-20 |
| Start Page: | 6s |
| Language: | English |
| ACCESSION: | WOS:000442916000002 |
| DOI: | 10.1200/JCO.2018.36.15_suppl.100 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 100 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
